Cancer Research AACR Membership Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Varon, R.
Right arrow Articles by Seeger, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Varon, R.
Right arrow Articles by Seeger, K.
[Cancer Research 61, 3570-3572, May 1, 2001]
© 2001 American Association for Cancer Research

Advances in Brief

Mutations in the Nijmegen Breakage Syndrome Gene (NBS1) in Childhood Acute Lymphoblastic Leukemia (ALL)1

Raymonda Varon, André Reis2, Günter Henze, Hagen Graf v. Einsiedel, Karl Sperling and Karlheinz Seeger

Institute of Human Genetics [R. V., A. R., K. Sp.] and Department of Pediatric Oncology/Hematology [G. H., H. G. v. E., K. Se.], Charité, Humboldt-University, 13353 Berlin, Germany, and Molecular Genetics and Gene Mapping Centre, Max-Delbrueck-Centre, 13092 Berlin, Germany [A. R.]


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 
The Nijmegen Breakage Syndrome (NBS) is a rare autosomal recessive disorder associated with immune deficiency, chromosome fragility, and increased susceptibility to lymphoid malignancies. The aim of the present study was to elucidate the potential role of the gene mutated in NBS (NBS1) in the pathogenesis and disease progression of childhood acute lymphoblastic leukemia (ALL). Samples from 47 children with first relapse of ALL were analyzed for mutations in all 16 exons of the NBS1 gene, and in 7 of them (14.9%), four novel amino acid substitutions were identified. Mutations S93L, D95N, and I171V occur in the two known domains of nibrin that are probably involved in protein-protein interactions. Germ-line origin of the I171V mutation was confirmed in three patients, whereas the D95N exchange was present only in leukemic cells. The R215W mutation was observed in one ALL but also in a population-based study and probably represents a rare sequence variant. No additional mutations were found on the second allele in any of these seven patients. The observed NBS1 gene mutations in ALL patients points to its possible involvement in the pathogenesis of this disease.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results and Discussion
 REFERENCES
 
ALL3 is the most common malignant disorder in childhood, with an overall excellent prognosis approaching 80% achieved by current multiagent treatment protocols. Twenty to 25% of children with ALL suffer a relapse. Genetically, leukemogenesis has been associated with specific chromosomal translocations such as t(9;22), t(1;19), and t(12;21) (1 , 2) or with rearrangements involving antigene receptor gene loci (immunoglobulin or T-cell receptor; Ref. 3 ). Increasingly, inherited mutations of genes coding for proteins involved in cell-cycle control, DNA damage repair, and apoptosis have been associated with an elevated predisposition to the development of malignancies (3) . Among these, tumor suppressor genes might also play a role in the pathogenesis of ALL (4) .

NBS is a chromosomal instability disorder characterized by microcephaly, immunodeficiency, radiation sensitivity, and high susceptibility to lymphoid malignancy. The gene product, nibrin, is a member of the hMRE11/RAD50 protein complex involved in DNA double-strand break repair and recombination (5) . Recently it has been shown that nibrin and ATM participate in a common pathway (6, 7, 8) . Thus far, two domains have been found in the NH2-terminal region of the protein—a FHA and a BRCT, both spanning the first 200 amino acids of nibrin (9) —that are also present in a number of other proteins involved in the cell cycle control (10 , 11) . On the basis of epidemiological data, it has been suggested that NBS heterozygotes also have an elevated cancer risk (12) similar to AT or other syndromes associated with immune deficiencies (4) . The findings that the ATM gene is involved in the pathogenesis of B-CLL (13 , 14) and T-cell prolymphocytic leukemia (15) as well as in breast cancer (16) implicate its role as a tumor suppressor gene. The high predisposition of NBS patients to lymphoid malignancy and the fact that the NBS and AT are indistinguishable at the cellular level (17) stimulated us to initiate a study that purposes to answer whether the NBS1 gene is involved in the pathogenesis of ALL and whether it influences the course of the disease and so has its place among the tumor suppressor genes.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results and Discussion
 REFERENCES
 
We analyzed bone marrow samples from 47 patients with first relapse of ALL (42 BCP-ALL and 5 T-ALL), mostly of German origin and unrelated to NBS families, for mutations in the NBS1 gene. All patients were enrolled in multicentric ALL relapse trials of the Berlin-Frankfurt-Münster study group (ALL-REZ BFM). Selection criteria were first relapse of ALL, bone marrow lymphoblasts >95%, and age <18 years. To disclose both the influence of NBS1 on outcome and the efficiency of frontline therapy, as well as its role in leukemogenesis and disease progression, the analysis of NBS1 mutations were primarily focused on relapsed childhood ALL. Informed written consent was obtained from either the parents or the guardians. DNA was extracted from bone marrow after Ficoll separation using a DNA extraction kit (Qiagen, GmbH, Hilden, Germany). All samples were analyzed by PCR-single strand conformation polymorphisms and partially by denaturing high pressure liquid chromatography analysis for all 16 exons of the NBS1 gene. The amplicons were electrophoresed on nondenaturing polyacrylamide gels as previously described (9) or analyzed on a denaturing high pressure liquid chromatography system (WAVE Transgenomic, Santa Clara, CA). The samples showing shifts with either method were directly sequenced. Mutations identified were also analyzed in germ-line DNA, when available, and in DNA samples of control individuals. In addition, we analyzed five highly polymorphic markers on chromosome 8q21, i.e., D8S271, D8S1800, D8S88, D8S1811, and D8S1724, by PCR with fluorescent-labeled primers and electrophoresis on sequencing gel (ALF; Pharmacia, Uppsala, Sweden).


   Results and Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
REFERENCES
 
Analysis of leukemic cell samples from 47 children with ALL revealed four novel single-base changes causing amino acid substitutions in bone marrow samples from 7 patients with first ALL relapse (5 of 42 BCP-ALL and 2 of 5 (pre-)T-ALL; Table 1Citation ). A transition C->T in exon 3 at nucleotide position 278 leading to mutation S93L was detected in patient 2897 with BCP-ALL. Another transition G->A in exon 3 at nucleotide position 283 leading to D95N was identified in patient 976 with BCP-ALL. Surprisingly, we found that four additional leukemic cell samples from unrelated ALL patients were heterozygous for the A->G at position 511 leading to I171V substitution in exon 5. These three newly identified mutations were not detected among 110 (S93L and D95N)) and among 220 (I171) control chromosomes analyzed. In one additional leukemic cell sample, a transition C->T at position 643 in exon 6 leading to amino acid change R215W was identified. This amino acid substitution was also found in nine probands of Slavic origin from a population-based study performed to estimate the prevalence of the major NBS1 mutation 657del5 (18) . However, despite the fact that this exchange results in a substitution of a basic to a nonpolar amino acid, it remains unclear whether this is a causative mutation or a rare sequence variant.


View this table:
[in this window]
[in a new window]

  		Table 1 NBS1 gene mutations in ALL and patients’ characteristics

 
Subsequently, we analyzed germ-line DNA samples to investigate whether the mutations found here were inherited or of somatic origin. Germ-line DNA was available for four of the patients. The constitutional genotype of patients 2796, 2253, and 2924 with the I171V mutation revealed that they were heterozygote carriers of this NBS1 mutation. In contrast, mutation D95N identified in patient 976 was not found in his normal cells, indicating that it arose de novo in the leukemic cell.

In comparison with patients with wt NBS1, children with mutated NBS1 tend to have late relapses (71.4% versus 45%) and an adverse outcome. Only 3 of 7 children with mutated NBS1 (43%) are in second complete remission relapse in contrast to 23 of 40 with wt NBS1 (58%). No significant differences could be detected between patients with mutated and wt NBS1 regarding sex, age at initial disease (median, 6.3 versus 5.5 years) and relapse (median, 9.2 versus 9.1 years), duration of last remission (2.91 versus 2.5 years), WBC (median, 6.4 versus 5.35 109/liter) and peripheral blast cell count (median, 0.4 versus 0.6 109/liter), site stratification into therapy groups, and frequency of bone marrow transplantation.

Three of the amino acid substitutions found here are of special interest, because they occur in the two currently known domains of nibrin (S93L and D95N in the FHA and I171V in the BRCT), which are believed to be involved in protein-protein interactions and thus are certainly important for nibrin function. In addition, the D95N and I117V substitutions affect amino acids known to be conserved in a number of proteins containing the FHA and BRCT domains (10 , 11) . The mutations described in our study are point mutations, unlike all mutations found thus far in NBS patients, which are truncating mutations and occur downstream of the FHA and BRCT domains (9) . Nevertheless, these point mutations could still inactivate some nibrin functions. Patients with AT also exhibit mostly truncating mutations (19) . In contrast, most of the ATM mutations found in patients with B-CLL, T-cell prolymphocytic leukemia, and breast cancer are missense mutations (13 , 15 , 20) . Given the high incidence of heterozygous NBS1 mutations in relapsed childhood ALL found here, we are presently analyzing a larger cohort of 60 patients with initial ALL. Thus far, we have found two samples heterozygous for the major NBS1 mutation 657del5 and one sample heterozygous for another point mutation, V210F in exon 6. Two of these mutations turned out to be of germ-line origin and one was a somatic mutation, substantiating our observations further.4

To investigate whether the NBS1 gene acts as a tumor suppressor gene, we searched for a second mutation in the seven patients. Because we failed to detect additional sequence variants, we analyzed the seven ALL samples and the corresponding DNA samples from normal cells obtained at remission for loss of heterozygosity with five highly polymorphic markers adjacent to the NBS1 gene. The samples were mostly heterozygous, or there was no difference between the genotypes of the leukemic cell samples and the germ-line DNA for the polymorphisms tested, thus excluding any major deletion of the NBS1 gene (Table 2)Citation . No loss of heterozygosity of the AT gene has been found in B-CLL patients, although reduction of ATM protein was demonstrated in most of the analyzed cases (13) .


View this table:
[in this window]
[in a new window]

  		Table 2 Analysis of loss of heterozygosity at 8q21

 
The novel NBS1 point mutations found in children with first-relapse ALL, as well as the truncated mutation found in patients with initial disease, combined with the putative nibrin function, suggest that the NBS1 gene might represent a susceptibility factor and be involved in the pathogenesis of ALL. A possible mechanisms leading to the inactivation of the NBS1 gene in ALL could be a dominant negative effect of the missense mutation (21) . Consequently, carriers of mutant NBS1 alleles possibly should avoid ionizing radiation and have their treatment protocols for malignant disease modified. However, to assess further the causative nature of the amino acid substitutions found here, functional experiments are in progress.


   ACKNOWLEDGMENTS
 
We are indebted to all of the patients for their participation in this study. We thank Catrin Janetzki and Claudia Hanel for their excellent technical assistance.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This study was supported by a grant from the Deutsche Forschungsgemeinschaft to Karl Sperling and André Reis and by a grant from the Deutsche Krebshilfe to Karlheinz Seeger and Günter Henze. Back

2 To whom requests for reprints should be addressed, at Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nürnberg, Schwabachanlage 10, 91054 Erlangen, Germany. Phone: 49-9131-8522318; Fax: 49-9131-209297; E-mail: reis{at}humgenet.uni-erlangen.de Back

3 The abbreviations used are: ALL, acute lymphoblastic leukemia; NBS, Nijmegen breakage syndrome; AT, ataxia teleangiectasia; ATM, AT-mutated; FHA, fork-head-associated domain; BRCT, breast cancer COOH-terminal domain; B-CLL, chromic lymphocytic leukemia; BCP, B-cell precursor; wt, wild-type. Back

4 Unpublished data. Back

Received 2/22/00. Accepted 3/13/01.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 

  1. Seeger K., Adams H. P., Buchwald D., Beyermann B., Kremens B., Niemeyer C., Ritter J., Schwabe D., Harms D., Schrappe M., Henze G. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Münster Study Group. Blood, 91: 1716-1722, 1998.[Abstract/Free Full Text]
  2. Beyermann B., Agthe A. G., Adams H. P., Seeger K., Linderkamp C., Goetze G., Ludwig W. D., Henze G. Clinical features and outcome of children with first marrow relapse of acute lymphoblastic leukemia expressing BCR-ABL fusion transcripts. BFM Relapse Study Group. Blood, 87: 1532-1538, 1996.[Abstract/Free Full Text]
  3. Offit K. Introduction to Cancer Genetics and Risk Assessment. American Society of Hematology, Education Program Book, : 9-17, American Society of Hematology New Orleans 1999.
  4. Vanasse G. J., Concannon P., Willerford D. M. Regulated genomic instability and neoplasia in the lymphoid lineage. Blood, 94: 3997-4010, 1999.[Free Full Text]
  5. Carney J. P., Maser R. S., Olivares H., Davis E. M., Le Beau M., Yates J. R., Hays L., Morgan W. F., Petrini J. H. The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell, 93: 477-486, 1998.[Medline]
  6. Gatei M., Young D., Cerosaletti K. M., Desai-Mehta A., Spring K., Kozlov S., Lavin M. F., Gatti R. A., Concannon P., Khanna K. ATM-dependent phosphorylation of nibrin in response to radiation exposure. Nat. Genet., 25: 115-119, 2000.[Medline]
  7. Zhao S., Weng Y. C., Yuan S. S., Lin Y. T., Hsu H. C., Lin S. C., Gerbino E., Song M. H., Zdzienicka M. Z., Gatti R. A., Shay J. W., Ziv Y., Shiloh Y., Lee E. Y. Functional link between ataxia-telangiectasia and Nijmegen breakage syndrome gene products. Nature (Lond.), 25: 473-477, 2000.
  8. Wu X., Ranganathan V., Weisman D. S., Heine W. F., Ciccone D. N., O’Neill T. B., Crick K. E., Pierce K. A., Lane W. S., Rathbun G., Livingston D. M., Weaver D. T. ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response. Nature (Lond.), 25: 477-482, 2000.
  9. Varon R., Vissinga C., Platzer M., Cerosaletti K. M., Chrzanowska K. H., Saar K., Beckmann G., Seemanova E., Cooper P. R., Nowak N. J., Stumm M., Weemaes C. M., Gatti R. A., Wilson R. K., Digweed M., Rosenthal A., Sperling K., Concannon P., Reis A. Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell, 93: 467-476, 1998.[Medline]
  10. Hofmann K., Bucher P. The FHA domain: a putative nuclear signalling domain found in protein kinases and transcription factors. Trends Biochem. Sci., 20: 347-349, 1995.[Medline]
  11. Bork P., Hofmann K., Bucher P., Neuwald A., Altschul S. F., Koonin E. V. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J., 11: 68-76, 1997.[Abstract]
  12. Seemanova E. An increased risk for malignant neoplasms in heterozygotes for a syndrome of microcephaly, normal intelligence, growth retardation, remarkable facies, immunodeficiency and chromosomal instability. Mutat. Res., 238: 321-324, 1990.[Medline]
  13. Stankovic T., Weber P., Stewart G., Bedenham T., Murray J., Byrd P. J., Moss P. A., Taylor A. M. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet, 353: 26-29, 1999.[Medline]
  14. Schaffner C., Stilgenbauer S., Rappold G. A., Dohner H., Lichter P. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood, 94: 748-753, 1999.[Abstract/Free Full Text]
  15. Vorechovsky I., Luo L., Dyer M. J., Catovsky D., Amlot P. L., Yaxley J. C., Foroni L., Hammarstrom L., Webster A. D., Yuille M. A. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. Nat. Genet., 17: 96-99, 1997.[Medline]
  16. Swift M., Su Y. Link between breast cancer and ATM gene is strong. BMJ, 318: 400 1999.[Free Full Text]
  17. Shiloh Y. Ataxia-telangiectasia and the Nijmegen breakage syndrome: related disorders but genes apart. Annu. Rev. Genet., 31: 635-662, 1997.[Medline]
  18. Varon R., Seemanova E., Chrzanowska K., Hnateyko O., Piekutowska-Abramczuk D., Krajewska-Walasek M., Sykut-Cegielska J., Sperling K., Reis A. Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slavic populations. EJHG, 8: 900-902, 2000.
  19. Concannon P., Gatti R. A. Diversity of ATM mutations detected in patients with ataxia-telangiectasia. Hum. Mutat., 10: 100-107, 1997.[Medline]
  20. Izatt L., Greenman J., Hodgson S., Ellis D., Watts S., Scott G., Jacobs C., Liebmann R., Zvelebil M. J., Mathew C., Solomon E. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chromosomes Cancer, 26: 286-294, 1999.[Medline]
  21. Meyn M. S. Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene. Clin. Genet., 55: 289-304, 1999.[Medline]



This article has been cited by other articles:


Home page
 haematolHome page
T. J. Gaymes, S. Shall, L. J. MacPherson, N. A. Twine, N. C. Lea, F. Farzaneh, and G. J. Mufti
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes
Haematologica, May 1, 2009; 94(5): 638 - 646.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
T. J. Gaymes, S. Shall, F. Farzaneh, and G. J. Mufti
Chromosomal instability syndromes are sensitive to poly ADP-ribose polymerase inhibitors
Haematologica, December 1, 2008; 93(12): 1886 - 1889.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Huang, M. A. Grotzer, T. Watanabe, E. Hewer, T. Pietsch, S. Rutkowski, and H. Ohgaki
Mutations in the Nijmegen Breakage Syndrome Gene in Medulloblastomas
Clin. Cancer Res., July 1, 2008; 14(13): 4053 - 4058.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
E. Seemanova, P. Jarolim, P. Seeman, R. Varon, M. Digweed, M. Swift, and K. Sperling
Cancer Risk of Heterozygotes With the NBN Founder Mutation
J Natl Cancer Inst, December 19, 2007; 99(24): 1875 - 1880.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
L. Kruger, I. Demuth, H. Neitzel, R. Varon, K. Sperling, K. H. Chrzanowska, E. Seemanova, and M. Digweed
Cancer incidence in Nijmegen breakage syndrome is modulated by the amount of a variant NBS protein
Carcinogenesis, January 1, 2007; 28(1): 107 - 111.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K. Heikkinen, K. Rapakko, S.-M. Karppinen, H. Erkko, S. Knuutila, T. Lundan, A. Mannermaa, A.-L. Borresen-Dale, A. Borg, R. B. Barkardottir, et al.
RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability
Carcinogenesis, August 1, 2006; 27(8): 1593 - 1599.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
E Seemanova, K Sperling, H Neitzel, R Varon, J Hadac, O Butova, E Schrock, P Seeman, and M Digweed
Nijmegen breakage syndrome (NBS) with neurological abnormalities and without chromosomal instability
J. Med. Genet., March 1, 2006; 43(3): 218 - 224.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M.-H. Yang, W.-C. Chiang, T.-Y. Chou, S.-Y. Chang, P.-M. Chen, S.-C. Teng, and K.-J. Wu
Increased NBS1 Expression Is a Marker of Aggressive Head and Neck Cancer and Overexpression of NBS1 Contributes to Transformation
Clin. Cancer Res., January 15, 2006; 12(2): 507 - 515.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y.-C. Chen, Y.-N. Su, P.-C. Chou, W.-C. Chiang, M.-C. Chang, L.-S. Wang, S.-C. Teng, and K.-J. Wu
Overexpression of NBS1 Contributes to Transformation through the Activation of Phosphatidylinositol 3-Kinase/Akt
J. Biol. Chem., September 16, 2005; 280(37): 32505 - 32511.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Cybulski, B. Gorski, T. Debniak, B. Gliniewicz, M. Mierzejewski, B. Masojc, A. Jakubowska, J. Matyjasik, E. Zlowocka, A. Sikorski, et al.
NBS1 Is a Prostate Cancer Susceptibility Gene
Cancer Res., February 15, 2004; 64(4): 1215 - 1219.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
K Heikkinen, S-M Karppinen, Y Soini, M Makinen, and R Winqvist
Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility
J. Med. Genet., December 1, 2003; 40(12): e131 - 131.
[Full Text]

Home page
 Cancer Res.Home page
G. M. Taylor, H. P. O'Brien, M. F. Greaves, P. F. Ravetto, and O. B. Eden
Correspondence re: R. Varon et al., Mutations in the Nijmegen breakage syndrome gene (NBS1) in childhood acute lymphoblastic leukemia. Cancer Res., 61: 3570-3572, 2001.
Cancer Res., October 1, 2003; 63(19): 6563 - 6564.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y.-C. Chiang, S.-C. Teng, Y.-N. Su, F.-J. Hsieh, and K.-J. Wu
c-Myc Directly Regulates the Transcription of the NBS1 Gene Involved in DNA Double-strand Break Repair
J. Biol. Chem., May 23, 2003; 278(21): 19286 - 19291.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Varon, R.
Right arrow Articles by Seeger, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Varon, R.
Right arrow Articles by Seeger, K.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online